 Neonatal screening sickle cell disease cost-effectiveness analysis PURPOSE cost-effectiveness newborn infants sickle cell disease DESIGN decision model strategies screening neonates penicillin infants cell disease hope pneumococcal sepsis penicillin infants symptoms sickle cell disease develop model cost-effectiveness strategies first years life model prototypic populations neonates black high prevalence hemoglobin genes low prevalence hemoglobin genes DATA IDENTIFICATION literature effectiveness risk penicillin prophylaxis risk pneumococcal sepsis probability infants development symptoms discovery sickle cell disease first years life published literature Hardy-Weinberg law prevalence sickle cell disease actual variable costs antibiotic prophylaxis hospitalization pneumococcal sepsis anaphylaxis RESULTS Screening black infants life nonblack populations high prevalence hemoglobin genes life low prevalence populations life CONCLUSIONS Screening black infants worthwhile populations hemoglobin gene rare unjustified